VitalTrace awarded $656,666 for the Clinical translation of a novel continuous lactate biosensor for fetal monitoring

VitalTrace was founded to improve the safety for mothers and babies during childbirth - babies being some of our youngest and most vulnerable patients. We are passionate about eliminating the unnecessary health, psychological and economic burdens from inaccurate childbirth monitoring. 

This project will progress development and clinical testing of a continuous lactate sensor, with the potential to revolutionise fetal monitoring during labour globally.

Current fetal monitoring technology is inaccurate, subjective and creates difficulties for clinicians leading to complications for mothers and babies. VitalTrace is developing DelivAssureTM, a breakthrough technology designed to continuously monitor clinically validated biomarkers to reduce fetal morbidities and wirelessly transmit readings to an associated display monitor.

The funding awarded through the Clinical Translation and Commercialisation Medtech grant, will help design and run VitalTrace's first clinical trial, testing DelivAssureTM, a novel continuous lactate biosensor, which has already received Breakthrough Device designation from the US FDA.

Previous
Previous

VitalTrace awarded $500,000 by the Future Health Research and Innovation (FHRI) Fund

Next
Next

VitalTrace receives $4M from the WA government to establish a new manufacturing facility